| Project/Area Number |
21590639
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | 財団法人東京都医学総合研究所 (2011)
Tokyo Metropolitan Organization for Medical Research (2009-2010) |
|---|
Principal Investigator |
KAWAKITA Masao 財団法人東京都医学総合研究所, ゲノム医科学研究分野, 研究員 (00012740)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HIRAMATSU Kyouko 財団法人東京都医学総合研究所, ゲノム医科学研究分野, 主任研究員 (80181189)
TAKAHASHI Kei-ichi 財団法人東京都医学総合研究所, ゲノム医科学研究分野,がん・感染症センター東京都立駒込病院外科, 客員研究員,部長 (60443115)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 尿検査 / 腫瘍マーカー / ポリアミン / ジアセチルスペルミン / 大腸がん / イムノクロマトグラフィー / 早期がん / 臨床検査 |
|---|
| Research Abstract |
N^1, N^<12>-diacetylspermine(DiAcSpm) in urine is frequently increased in cancer patients at earlier stages of the disease and hence is considered as promising tumor marker. In the present study we first analyzed the urinary DiAcSpm level of healthy persons in detail, and established cut-off values to distinguish between normal and abnormal levels of DiAcSpm excretion. We then developed an immunochromatographic device for simple and rapid DiAcSpm determination. The spreading of this simple determination procedure may help in increasing the opportunity of early detection of cancer patients. Our further analysis revealed that DiAcSpm is increased in cancer tissues from very early stages of cancer development. This finding provides us with a new method for early cancer detection on one hand, and a useful clue to answer the question of why DiAcSpm is increased in the urine from early cancer patients.
|
